Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS

Abstract: CPX-351 has been approved for patients with therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (MRC-AML). No extensive data are available on measurable residual disease (MRD) and long-term clinical outcome using CPX-351 in AML in real life. We retrosp...

Deskribapen osoa

Xehetasun bibliografikoak

Egile Nagusiak:	Thomas Cluzeau, Fabio Guolo, Edmond Chiche, Paola Minetto, Ramy Rahme, Sarah Bertoli, Luana Fianchi, Jean-Baptiste Micol, Michele Gottardi, Pierre Peterlin, Sara Galimberti, Xavier Thomas, Giuliana Rizzuto, Olivier Legrand, Michela Rondoni, Emmanuel Raffoux, Giambattista Bertani, Alexis Caulier, Michelina D’Argenio, Caroline Bonmati, Atto Billio, Caroline Lejeune, Barbara Scappini, Arnaud Pigneux, Patrizia Zappasodi, Christan Recher, Francesco Grimaldi, Lionel Ades, Roberto M. Lemoli
Formatua:	Artigo
Hizkuntza:	Inglês
Argitaratua:	Elsevier 2025-02-01
Saila:	Blood Advances
Sarrera elektronikoa:	http://www.sciencedirect.com/science/article/pii/S2473952924006293
Etiketak:	Etiketa erantsi Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!